Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck’s ifinatamab deruxtecan for patients with pretreated extensivestage SCLC: Tokyo Tuesday, August 19, 2025 ...

Developed by Daiichi Sankyo and Merck, it treats patients with Pretreated Extensive-Stage Small Cell Lung Cancer.

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

However, AbbVie has also built a substantial oncology franchise with products like Imbruvica and Venclexta. Some key oncology ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...

Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.